SCHEMBL7123715

SCHEMBL7123715

CCCCCCC(C)CC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.78
CYP3A4 P08684 7/20 0.71
TSHR P16473 5/20 0.71
MAPT P10636 5/20 0.71
NR3C1 P04150 4/20 0.71
PGR P06401 4/20 0.71
AR P10275 4/20 0.71
NR1I2 O75469 3/20 0.71
CYP17A1 P05093 3/20 0.71
CYP2C9 P11712 3/20 0.71
CYP2C19 P33261 2/20 0.71
OPRK1 P41145 1/20 0.71
CYP19A1 P11511 3/20 0.68
HSD17B10 Q99714 3/20 0.55
SHBG P04278 3/20 0.55
SERPINA6 P08185 3/20 0.55
GPBAR1 Q8TDU6 3/20 0.55
SIGMAR1 Q99720 3/20 0.55
MAPK1 P28482 3/20 0.55
SNCA P37840 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7125292 1.00 LMNA (0.78) LMNACYP3A4TSHRMAPTNR3C1
SCHEMBL19582789 0.89 LMNA (0.74) LMNACYP3A4TSHRMAPTNR3C1
SCHEMBL5664295 0.88 LMNA (0.75) LMNACYP3A4TSHRMAPTNR3C1
SCHEMBL5664622 0.88 LMNA (0.75) LMNACYP3A4TSHRMAPTNR3C1
Testosterone Enanthate SCHEMBL19644909 0.88 LMNA (1.00) LMNACYP3A4TSHRMAPTNR3C1
SCHEMBL17537539 0.88 LMNA (1.00) LMNACYP3A4TSHRMAPTNR3C1
SCHEMBL17541885 0.88 LMNA (1.00) LMNACYP3A4TSHRMAPTNR3C1
Testosterone Undecanoate SCHEMBL17545317 0.88 LMNA (1.00) LMNACYP3A4TSHRMAPTNR3C1
SCHEMBL17541905 0.88 LMNA (1.00) LMNACYP3A4TSHRMAPTNR3C1
Testosterone Undecanoate SCHEMBL5491530 0.88 LMNA (1.00) LMNACYP3A4TSHRMAPTNR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030022875-A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness VIVUS INC. 2003-01-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022875-A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness SHBG, FSHR, GNRHR LMNA 4836/4885CYP3A4 316/4885TSHR 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.